<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: financial condition", fill: "#fbaed2"},
{source: "2: financial condition", target: "2: operations could", fill: "#fbaed2"},
{source: "2: operations could", target: "2: materially adversely affected by", fill: "#fbaed2"},
{source: "2: financial condition", target: "4: should refer", fill: "#fe28a2"},
{source: "4: should refer", target: "4: explanation", fill: "#fe28a2"},
{source: "4: explanation", target: "4: qualifications", fill: "#fe28a2"},
{source: "4: qualifications", target: "4: limitations on forwardlooking", fill: "#fe28a2"},
{source: "4: limitations on forwardlooking", target: "4: statements set forth immediately prior", fill: "#fe28a2"},
{source: "4: statements set forth immediately prior", target: "4: Annual Report ", fill: "#fe28a2"},
{source: "4: Annual Report ", target: "4: Additional ", fill: "#fe28a2"},
{source: "4: Additional ", target: "4: presently known", fill: "#fe28a2"},
{source: "4: presently known", target: "4: immaterial may also adversely affect", fill: "#fe28a2"},
{source: "4: immaterial may also adversely affect", target: "4: financial condition", fill: "#fe28a2"},
{source: "4: financial condition", target: "4: operations", fill: "#fe28a2"},
{source: "4: should refer", target: "6: products development activities", fill: "#f0e68c"},
{source: "6: products development activities", target: "6: manufacturing processes", fill: "#f0e68c"},
{source: "6: manufacturing processes", target: "6: rigorous regulation by", fill: "#f0e68c"},
{source: "6: rigorous regulation by", target: "6: by comparable agencies", fill: "#f0e68c"},
{source: "6: by comparable agencies", target: "6: foreign countries", fill: "#f0e68c"},
{source: "6: foreign countries", target: "6: regulatory agencies", fill: "#f0e68c"},
{source: "6: regulatory agencies", target: "6: governing bodies", fill: "#f0e68c"},
{source: "6: products development activities", target: "11: discovery", fill: "#ff0"},
{source: "11: discovery", target: "11: previously unknown problems with", fill: "#ff0"},
{source: "11: previously unknown problems with", target: "11: manufacturer could", fill: "#ff0"},
{source: "11: manufacturer could", target: "11: fines delays", fill: "#ff0"},
{source: "11: fines delays", target: "11: suspensions", fill: "#ff0"},
{source: "11: suspensions", target: "11: regulatory", fill: "#ff0"},
{source: "11: regulatory", target: "11: clearances", fill: "#ff0"},
{source: "11: clearances", target: "11: restrictions andor criminal prosecution", fill: "#ff0"},
{source: "11: discovery", target: "23: Patents ", fill: "#e30b5d"},
{source: "23: Patents ", target: "23: proprietary", fill: "#e30b5d"},
{source: "23: proprietary", target: "23: compete effectively with", fill: "#e30b5d"},
{source: "23: compete effectively with", target: "23: companies will", fill: "#e30b5d"},
{source: "23: companies will", target: "23: dependent upon", fill: "#e30b5d"},
{source: "23: dependent upon", target: "23: technologies", fill: "#e30b5d"},
{source: "23: Patents ", target: "40: future growth", fill: "#ff0800"},
{source: "40: future growth", target: "40: dependent upon", fill: "#ff0800"},
{source: "40: dependent upon", target: "40: development", fill: "#ff0800"},
{source: "40: development", target: "40: new products which", fill: "#ff0800"},
{source: "40: new products which", target: "40: significant", fill: "#ff0800"},
{source: "40: significant", target: "40: development clinical trials", fill: "#ff0800"},
{source: "40: development clinical trials", target: "40: regulatory approvals", fill: "#ff0800"},
{source: "40: regulatory approvals", target: "40: timeconsuming", fill: "#ff0800"},
{source: "40: timeconsuming", target: "40: commercially viable product", fill: "#ff0800"},
{source: "40: future growth", target: "START_HERE", fill: "#ff0800"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_focus_theory">Regulatory focus theory</a></td>
      <td>Regulatory focus theory (RFT) is a theory of goal pursuit: 444  formulated by Columbia University psychology professor and researcher E. Tory Higgins regarding people's perceptions in the decision making process. RFT examines the relationship between the motivation of a person and the way in which they go about achieving their goal.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gene_regulatory_network">Gene regulatory network</a></td>
      <td>A gene (or genetic) regulatory network (GRN) is a collection of molecular regulators that interact with each other and with other substances in the cell to govern the gene expression levels of mRNA and proteins which, in turn, determine the function of the cell. GRN also play a central role in morphogenesis, the creation of body structures, which in turn is central to evolutionary developmental biology (evo-devo).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MISONIX INC      Item 1A Risk Factors       In addition to the other information contained in this Form 10-K and the     <font color="blue">exhibits hereto</font>, the <font color="blue">following risk factors should</font> be considered <font color="blue">carefully</font>     in evaluating our business</td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">financial condition</font> or results of     <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue"><font color="blue">materially <font color="blue">adversely</font> affected</font> by</font> any of these risks</td>
    </tr>
    <tr>
      <td>You <font color="blue">should refer</font> to the     <font color="blue">explanation</font>  of  the <font color="blue">qualifications</font> and <font color="blue">limitations on</font> forward-looking     <font color="blue">statements set forth immediately prior</font> to the beginning of Item 1 of this     <font color="blue">Annual Report </font>on Form 10-K <font color="blue">Additional </font>risks not <font color="blue">presently known</font> to us or     that we currently deem <font color="blue">immaterial may also <font color="blue">adversely</font> affect</font> our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       We are subject to extensive medical device <font color="blue">regulation which may impede</font> or     hinder the approval process for our products and, in some cases, may not     ultimately result in approval or may result in the recall or seizure of     <font color="blue">previously approved products</font></td>
    </tr>
    <tr>
      <td>Our products, <font color="blue">development</font> activities and <font color="blue"><font color="blue">manufacturing</font> processes</font> are subject     to extensive and <font color="blue">rigorous regulation by</font> the FDA pursuant to the Federal     Food,  Drug, and Cosmetic Act (the FDC Act), <font color="blue">by comparable agencies</font> in     <font color="blue">foreign countries</font>, and by other <font color="blue"><font color="blue">regulatory</font> agencies</font> and <font color="blue">governing bodies</font></td>
    </tr>
    <tr>
      <td>Under the FDC Act, <font color="blue"><font color="blue">medical devices</font> must</font> receive FDA clearance or approval     before they can be <font color="blue">commercially</font> marketed in the US In addition, most major     markets for <font color="blue"><font color="blue">medical devices</font> outside</font> the US require clearance, approval or     <font color="blue">compliance with certain standards</font> before a product can be <font color="blue">commercially</font>     marketed</td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">marketing approval</font> or <font color="blue">clearance from</font> the     FDA for <font color="blue">new products</font>, or with respect to <font color="blue">enhancements</font> or <font color="blue">modifications</font> to     existing products, could:       §     take a <font color="blue">significant</font> period of time;       §     require the <font color="blue">expenditure</font> of substantial resources;       §     involve rigorous pre-clinical and clinical testing;       §     require changes to the products; and       §     result in <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> of the products</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________           Even after products have received <font color="blue">marketing approval</font> or clearance, product     approvals and <font color="blue"><font color="blue">clearances</font> by</font> the FDA can be <font color="blue">withdrawn due</font> to failure to     <font color="blue">comply with <font color="blue">regulatory</font> standards</font> or the occurrence of <font color="blue">unforeseen problems</font>     <font color="blue">following initial approval</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will receive     the required <font color="blue"><font color="blue">clearances</font> from</font> the FDA for <font color="blue">new products</font> or <font color="blue">modifications</font> to     existing products on a timely basis or that any FDA <font color="blue">approval will</font> not be     <font color="blue">subsequently withdrawn</font></td>
    </tr>
    <tr>
      <td>Later <font color="blue">discovery</font> of <font color="blue">previously unknown problems with</font>     a product or <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font> could</font> result in fines, delays or <font color="blue">suspensions</font> of     <font color="blue">regulatory</font>  <font color="blue">clearances</font>,  seizures  or  recalls  of products, operating     restrictions and/or criminal prosecution</td>
    </tr>
    <tr>
      <td>The failure to receive product     <font color="blue">approval clearance on</font> a timely basis, <font color="blue">suspensions</font> of <font color="blue">regulatory</font> <font color="blue">clearances</font>,     seizures or recalls of products or the withdrawal of <font color="blue">product approval by</font> the     FDA  could  have  a material adverse effect on our business, financial     condition or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not meet <font color="blue">regulatory</font> quality standards applicable to our <font color="blue">manufacturing</font>     and quality processes, <font color="blue">which could</font> have an adverse effect on our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As a device <font color="blue"><font color="blue">manufacture</font>r</font>, w are required to register with the FDA and are     subject to periodic inspection by the FDA for compliance with the FDA’s     Quality System Regulation (QSR) <font color="blue">requirements</font>, which require <font color="blue"><font color="blue">manufacture</font>r</font>s of     <font color="blue">medical devices</font> to adhere to <font color="blue">certain <font color="blue">regulations</font></font>, including testing, quality     control and <font color="blue">documentation procedures</font></td>
    </tr>
    <tr>
      <td>In addition, the federal Medical     Device Reporting <font color="blue">regulations</font> require us to provide information to the FDA     <font color="blue">whenever there</font> is evidence that <font color="blue">reasonably</font> suggests that a device may have     caused or contributed to a death or <font color="blue">serious injury</font> or, if a <font color="blue">malfunction</font> were     to occur, could cause or contribute to a death or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance     </font>with applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> is subject to <font color="blue">continual review</font> and     is <font color="blue">rigorously monitored through periodic inspections by</font> the FDA In the     European Community, we are required to maintain certain ISO <font color="blue">certifications</font>     in order to sell our products and <font color="blue">must undergo periodic inspections by</font>     <font color="blue">notified bodies</font> to obtain and maintain these <font color="blue">certifications</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue"><font color="blue">intellectual</font> <font color="blue">property <font color="blue">litigation</font></font> could</font> be costly and <font color="blue">disruptive</font> to     us</td>
    </tr>
    <tr>
      <td>We operate in an industry that is susceptible to <font color="blue">significant</font> <font color="blue">intellectual</font>     <font color="blue">property <font color="blue">litigation</font></font> and, in <font color="blue">recent years</font>, it has <font color="blue">been common</font> for companies     in the medical device field to <font color="blue">aggressively challenge</font> the <font color="blue">patent rights</font> of     other  companies  in  order  to  prevent the marketing of new devices</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property <font color="blue">litigation</font></font> is expensive, complex and lengthy and its     outcome is <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>Future <font color="blue">patent <font color="blue">litigation</font> may</font> result in     <font color="blue">significant</font> royalty or other payments or <font color="blue">injunctions</font> that can prevent the     sale of products and may <font color="blue">significant</font>ly divert the attention of our technical     and <font color="blue">management personnel</font></td>
    </tr>
    <tr>
      <td>In the event that our right to market any of our     products is <font color="blue">successfully challenged</font>, and if we fail to obtain a required     license or are unable to <font color="blue">design around</font> a patent, our business, financial     condition or results of <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue">materially <font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We may not be <font color="blue">able <font color="blue">effective</font>ly</font> to protect our <font color="blue"><font color="blue">intellectual</font> property rights</font>     <font color="blue">which could</font> have an adverse effect on our business, <font color="blue">financial condition</font> or     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Patents  </font>and other <font color="blue">proprietary</font> rights are and will be essential to our     business, and our ability to <font color="blue">compete <font color="blue">effective</font>ly with</font> other <font color="blue">companies will</font>     be <font color="blue">dependent upon</font> the <font color="blue">proprietary</font> nature of our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We rely upon     trade secrets, know-how, continuing <font color="blue">technological</font> innovations, strategic     alliances and <font color="blue">licensing <font color="blue">opportunities</font></font> to develop, maintain and strengthen     our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>We pursue a policy of <font color="blue">generally</font> obtaining patent     protection in both the US and abroad for patentable subject matter in our     <font color="blue">proprietary</font> devices and also attempt to review third-party patents and     patent <font color="blue">applications</font> to the <font color="blue">extent publicly available</font> to develop an <font color="blue">effective</font>     patent  strategy,  <font color="blue">avoid infringement</font> of third-party patents, identify     licensing  <font color="blue">opportunities</font>  and  monitor the patent claims of others</td>
    </tr>
    <tr>
      <td>We also are party to     various  license  <font color="blue">agreements pursuant</font> to which <font color="blue">patent rights</font> have been     obtained  or granted in <font color="blue">consideration</font> for cash or <font color="blue">royalty payments</font></td>
    </tr>
    <tr>
      <td>No     assurance can be made that any pending or future patent <font color="blue">applications</font> will     result in <font color="blue">issued patents</font>, that any current or <font color="blue">future patents issued</font> to, or     licensed by, us will not be challenged or <font color="blue">circumvented by</font> our <font color="blue">competitors</font>,     or that our <font color="blue">patents will</font> not be <font color="blue">found invalid</font></td>
    </tr>
    <tr>
      <td>In addition, we may have to take <font color="blue">legal action</font> in the future to protect our     patents,  trade  secrets or know-how or to assert <font color="blue">them against</font> claimed     <font color="blue">infringement by others</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">legal action</font> of that type could be costly and     time consuming to us and <font color="blue">no assurances</font> can be made that any <font color="blue">lawsuit will</font> be     successful</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________       The invalidation of <font color="blue">key patents</font> or <font color="blue">proprietary</font> rights that we own, or an     <font color="blue"><font color="blue">unsuccessful</font> outcome</font> in lawsuits to protect our <font color="blue">intellectual</font> property, could     have  a material adverse effect on our business, <font color="blue">financial position</font> or     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">product <font color="blue">liability</font></font> claims and other <font color="blue">litigation</font>, including private     securities <font color="blue">litigation</font> and shareholder derivative suits, may <font color="blue">adversely</font> affect     our business, reputation and ability to attract and retain customers</td>
    </tr>
    <tr>
      <td>The design, <font color="blue">manufacture</font> and marketing of <font color="blue">medical devices</font> of the types that     we produce entail and <font color="blue">inherent risk</font> of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>A number of     <font color="blue">factors could</font> results in an <font color="blue">unsafe condition</font> or injury to, or death of, a     <font color="blue">patient with respect</font> to these or other products that we <font color="blue">manufacture</font> or sell,     including  component  failures, <font color="blue">manufacturing</font> flaws, design defects or     inadequate  <font color="blue">disclosure</font>  of  product-related  risks  or product-related     information</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> result in <font color="blue">product <font color="blue">liability</font></font> claims, a     recall of one or more of our products or a <font color="blue">safety alert</font> relating to one or     more of our products</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims may be <font color="blue">brought by individuals</font>     or <font color="blue">by groups seeking</font> to represent a class</td>
    </tr>
    <tr>
      <td>We may not be successful in our <font color="blue">strategic initiatives</font> to <font color="blue">become primarily</font> a     medical device company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategic initiatives</font> intend to <font color="blue">further expand</font> our ability to offer     customers <font color="blue">effective</font>, quality <font color="blue">medical devices</font> that satisfy their needs, as     well  as  focus  the Company on our medical device platform</td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">unsuccessful</font> in our <font color="blue">strategic initiatives</font>, we may be unable to continue to     grow our business <font color="blue">significant</font>ly or <font color="blue">may record asset impairment charges</font> in     the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future growth</font> is <font color="blue">dependent upon</font> the <font color="blue">development</font> of <font color="blue">new products</font>, which     requires  <font color="blue">significant</font>  research  and  <font color="blue">development</font>, clinical trials and     <font color="blue">regulatory</font> approvals, all of which are very expensive and time-consuming and     may not result in a <font color="blue">commercially</font> viable product</td>
    </tr>
    <tr>
      <td>In order to develop <font color="blue">new products</font> and <font color="blue">improve current product offerings</font>, we     focus our research and <font color="blue">development</font> programs largely on the <font color="blue">development</font> of     next-generation and novel technology offerings across multiple programs and     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We expect to launch our <font color="blue">bone cutter product</font> for <font color="blue">laminectomies</font>     during  the  first  calendar quarter 2007</td>
    </tr>
    <tr>
      <td>We currently are performing     <font color="blue">clinicals on</font> the product</td>
    </tr>
    <tr>
      <td>We are also performing clinicals for <font color="blue">kidney cancer</font>     treatment in Europe</td>
    </tr>
    <tr>
      <td>Further, we anticipate continuing our <font color="blue">increased focus</font> and <font color="blue">spending on areas</font>     such as HIFU <font color="blue">technologies</font> for the kidney, liver and breast</td>
    </tr>
    <tr>
      <td>However, given     their <font color="blue">early stage</font> of <font color="blue">development</font>, there can be no assurance that these and     other <font color="blue">technologies</font> will achieve <font color="blue"><font color="blue">technological</font> feasibility</font>, obtain <font color="blue">regulatory</font>     approval or <font color="blue">gain market acceptance</font></td>
    </tr>
    <tr>
      <td>A delay in the <font color="blue">development</font> or approval     of these <font color="blue">technologies</font> or our decision to <font color="blue">reduce funding</font> of these projects     <font color="blue">may <font color="blue">adversely</font> impact</font> the <font color="blue">contribution</font> of these <font color="blue">technologies</font> to our future     growth</td>
    </tr>
    <tr>
      <td>As a part of the <font color="blue">regulatory</font> process of obtaining marketing <font color="blue">clearance from</font>     the FDA for <font color="blue">new products</font>, we conduct and <font color="blue">participate</font> in numerous clinical     trials  with a variety of study designs, patient <font color="blue">populations</font> and trial     <font color="blue">endpoints</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unfavorable </font>or inconsistent clinical data from existing or future     clinical trials conducted by us, by our <font color="blue">competitors</font> or by third parties, or     the market’s <font color="blue">perception</font> of this clinical data, <font color="blue">may <font color="blue">adversely</font> impact</font> our     ability to obtain product approvals from the FDA, our position in, and share     of,  the  markets  in which we <font color="blue">participate</font> and our business, financial     condition, results of <font color="blue">operations</font> or <font color="blue">future prospects</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font></font> and may not be able to keep pace with the rapid     <font color="blue">technological</font> changes in the <font color="blue">medical devices</font> industry, <font color="blue">which could</font> have an     adverse  effect  on  our  business,  <font color="blue">financial condition</font> or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________           The medical device market is <font color="blue">highly <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>We encounter <font color="blue">significant</font>     <font color="blue">competition</font>  across  our <font color="blue">product lines</font> and in <font color="blue">each market</font> in which our     products are <font color="blue">sold from various medical</font> device companies, some of which may     have <font color="blue">greater financial</font> and <font color="blue">marketing resources than</font> we do</td>
    </tr>
    <tr>
      <td>Additionally,  the medical device market is <font color="blue">characterized</font> by extensive     research and <font color="blue">development</font>, and rapid <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font>by     other companies of new or improved products, processes or <font color="blue">technologies</font>, in     particular in the cancer treatment market, may make our products or proposed     products  obsolete  or  <font color="blue">less <font color="blue">competitive</font></font> and <font color="blue">may negatively impact</font> our     revenues</td>
    </tr>
    <tr>
      <td>We  are  required to <font color="blue">devote continued efforts</font> and financial     resources to develop or acquire scientifically advanced <font color="blue">technologies</font> and     products, apply our <font color="blue">technologies</font> cost-<font color="blue">effective</font>ly across <font color="blue">product lines</font> and     markets, attract and retain skilled <font color="blue">development</font> personnel, obtain patent and     other  protection  for  our <font color="blue">technologies</font> and products, obtain required     <font color="blue">regulatory</font> and <font color="blue"><font color="blue">reimbursement</font> approvals</font> and successfully <font color="blue">manufacture</font> and     market our products</td>
    </tr>
    <tr>
      <td>Failure to develop <font color="blue">new products</font> or enhance existing     products could have a material adverse effect on our business, financial     condition or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because we derive a <font color="blue">significant</font> amount of our <font color="blue">revenues from <font color="blue">international</font></font>     <font color="blue">operations</font> and a <font color="blue">significant</font> percentage of our growth is expected to come     from  <font color="blue">international</font>  <font color="blue">operations</font>,  changes in <font color="blue"><font color="blue">international</font> economic</font> or     <font color="blue">regulatory</font>  <font color="blue">conditions</font>  could  have a material <font color="blue">impact on</font> our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Additionally, a <font color="blue">significant</font> percentage of our <font color="blue">future growth</font> is     expected  to  come  from  <font color="blue">international</font>  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As a result, our     <font color="blue">profitability</font> from our <font color="blue">international</font> <font color="blue">operations</font> may be limited by risks and     <font color="blue">uncertainties</font> related to economic <font color="blue">conditions</font> in these regions, foreign     currency <font color="blue">fluctuations</font>, <font color="blue">regulatory</font> and <font color="blue"><font color="blue">reimbursement</font> approvals</font>, <font color="blue">competitive</font>     offerings, <font color="blue">infrastructure</font> <font color="blue">development</font>, rights to <font color="blue">intellectual</font> property and     our  ability  to  implement  our  overall  business strategy</td>
    </tr>
    <tr>
      <td>Further,     <font color="blue">international</font>  markets are also being <font color="blue">affected by economic pressure</font> to     contain <font color="blue">reimbursement</font> levels and <font color="blue">healthcare costs</font></td>
    </tr>
    <tr>
      <td>The trend in countries     around  the  world,  including Japan, toward more stringent <font color="blue">regulatory</font>     <font color="blue">requirements</font> for <font color="blue">product clearance</font>, changing <font color="blue">reimbursement</font> models and more     <font color="blue">rigorous inspection</font> and <font color="blue">enforcement activities</font> has <font color="blue">generally</font> caused or may     cause medical device <font color="blue"><font color="blue">manufacture</font>r</font>s to experience more uncertainty, delay,     risk and expense</td>
    </tr>
    <tr>
      <td><font color="blue">Consolidation </font>in the <font color="blue"><font color="blue">healthcare industry</font> could lead</font> to demands for price     <font color="blue">concessions</font>  or  the  exclusion  of some <font color="blue">suppliers from certain</font> of our     <font color="blue">significant</font> market segments, <font color="blue">which could</font> have an adverse effect on our     business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The cost of healthcare has risen <font color="blue">significant</font>ly over the past decade and     <font color="blue">numerous initiatives</font> and reforms initiated by legislators, regulators and     third-party payers to curb these costs have resulted in a <font color="blue">consolidation</font>     trend in the <font color="blue">healthcare industry</font>, including hospitals</td>
    </tr>
    <tr>
      <td>This in turn has     resulted in greater pricing pressures and the exclusion of <font color="blue">certain suppliers</font>     from  important  market  segments  as  group <font color="blue">purchasing organizations</font>,     <font color="blue">independent</font>  delivery  networks  and large <font color="blue">single accounts continue</font> to     <font color="blue">consolidate purchasing decisions</font> for some of our <font color="blue">hospital customers</font></td>
    </tr>
    <tr>
      <td>We     expect that market demand, government regulation, third-party <font color="blue">reimbursement</font>     policies  and <font color="blue">societal pressures will continue</font> to change the worldwide     healthcare  industry, resulting in further business <font color="blue">consolidation</font>s and     <font color="blue">alliances among</font> our customers and <font color="blue">competitors</font>, which may reduce <font color="blue">competition</font>,     exert  <font color="blue">further downward pressure on</font> the prices of our products and may     <font color="blue">adversely</font> impact our business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>